GlassScriptPhysician profile
Vaughn E Hanna
NPI 1912912213
$42,222.01
in general payments reported to CMS, 2019-2025
22 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,538 · 2021: $6,780 · 2022: $14K · 2023: $2,391 · 2024: $529 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,625 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,625.00 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,305.14 | 2019-2025 | |
| Amgen INC. | $1,758.39 | 2019-2025 | Evenity, Tavneos, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.52 | 2020-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $405.74 | 2019-2023 | |
| Ucb, INC. | $356.90 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $333.85 | 2019-2023 | Benlysta |
| Janssen Scientific Affairs, LLC | $205.25 | 2021-2022 | |
| Janssen Biotech, INC. | $189.88 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $171.61 | 2019-2025 | Orencia |
| Radius Health, INC. | $164.78 | 2019-2024 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $154.29 | 2022-2023 | Saphnelo |
| Lilly USA, LLC | $141.43 | 2019-2023 | Taltz |
| Pfizer INC. | $137.78 | 2019-2022 | |
| Genzyme Corporation | $104.50 | 2019-2020 | |
| Genentech USA, INC. | $89.01 | 2019-2025 | Gazyva |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $73.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $28.63 | 2019 | |
| Organon LLC | $19.92 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.48 | 2025 | Lupkynis |
| Pacira Therapeutics, INC. | $19.07 | 2019 | |
| Celgene Corporation | $15.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaughn Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.